EA201200473A1 - Замещенные (гетероарилметил)тиогидантоины - Google Patents

Замещенные (гетероарилметил)тиогидантоины

Info

Publication number
EA201200473A1
EA201200473A1 EA201200473A EA201200473A EA201200473A1 EA 201200473 A1 EA201200473 A1 EA 201200473A1 EA 201200473 A EA201200473 A EA 201200473A EA 201200473 A EA201200473 A EA 201200473A EA 201200473 A1 EA201200473 A1 EA 201200473A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituted
thiogidantoines
heteroarilmethyl
preparation
treatment
Prior art date
Application number
EA201200473A
Other languages
English (en)
Inventor
Ульрих Люккинг
Арвед Клеве
Бернар Эндлер
Ортенсия Фаус-Гименес
Зильке Кёр
Хорст Ирльбахер
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201200473A1 publication Critical patent/EA201200473A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Изобретение относится к замещенным соединениям (гетероарилметил)тиогидантоина общей формулы (I), как описано и определено в данной заявке, и способам их получения, их применению для лечения и/или профилактики нарушений и их применению для приготовления лекарственных средств для лечения и/или профилактики нарушений, в частности рака предстательной железы.
EA201200473A 2009-09-11 2010-08-28 Замещенные (гетероарилметил)тиогидантоины EA201200473A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Publications (1)

Publication Number Publication Date
EA201200473A1 true EA201200473A1 (ru) 2012-10-30

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200473A EA201200473A1 (ru) 2009-09-11 2010-08-28 Замещенные (гетероарилметил)тиогидантоины

Country Status (27)

Country Link
US (1) US20120251551A1 (ru)
EP (1) EP2475653A1 (ru)
JP (1) JP2013504523A (ru)
KR (1) KR20120065396A (ru)
CN (1) CN102639523A (ru)
AR (1) AR078166A1 (ru)
AU (1) AU2010294588A1 (ru)
BR (1) BR112012005526A2 (ru)
CA (1) CA2773591A1 (ru)
CL (1) CL2012000623A1 (ru)
CO (1) CO6511228A2 (ru)
CR (1) CR20120113A (ru)
CU (1) CU20120042A7 (ru)
DO (1) DOP2012000063A (ru)
EA (1) EA201200473A1 (ru)
EC (1) ECSP12011716A (ru)
IL (1) IL218390A0 (ru)
IN (1) IN2012DN02081A (ru)
MA (1) MA33566B1 (ru)
MX (1) MX2012002977A (ru)
NZ (1) NZ598643A (ru)
PE (1) PE20121180A1 (ru)
SG (1) SG178919A1 (ru)
TN (1) TN2012000108A1 (ru)
TW (1) TW201111378A (ru)
UY (1) UY32882A (ru)
WO (1) WO2011029537A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012020311B1 (pt) 2010-02-17 2019-01-29 Takeda Pharmaceutical Company Limited composto heterocíclico fundido tendo uma atividade inibidora de ciclo 7 de divisão celular forte (cdc7), e, medicamento compreendendo o mesmo
US9199976B2 (en) * 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
EP3466959A1 (en) 2011-12-22 2019-04-10 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2597757T3 (es) 2012-05-25 2017-01-20 Janssen Sciences Ireland Uc Nucleósidos de uracilespirooxetano
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
EA201590943A1 (ru) 2012-12-21 2016-01-29 Алиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
EP3080100B1 (en) * 2013-12-11 2022-11-30 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
EP3083596A1 (en) 2013-12-18 2016-10-26 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
AU2015257917C1 (en) 2014-05-07 2019-03-14 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
US10214542B2 (en) 2015-10-08 2019-02-26 Bayer Pharma Aktiengesellschaft Modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2018177899A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
WO2018211442A1 (en) 2017-05-18 2018-11-22 Pi Industries Ltd. Formimidamidine compounds useful against phytopathogenic microorganisms
EA202091894A1 (ru) 2018-02-13 2020-12-28 Байер Акциенгезельшафт Применение 5-фтор-4-(4-фтор-2-метоксифенил)-n-{4-[(s-метилсульфонимидоил)метил]пиридин-2-ил}пиридин-2-амина для лечения диффузной в-крупноклеточной лимфомы
EP3953342A4 (en) * 2019-04-11 2023-01-11 University of Miami IMPROVED NOTCH TRANSCRIPTION ACTIVATION COMPLEX INHIBITORS AND METHODS OF USE THEREOF
US20230135524A1 (en) * 2020-01-21 2023-05-04 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
WO2022206742A1 (zh) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
KR100660309B1 (ko) 1998-09-22 2006-12-22 아스텔라스세이야쿠 가부시키가이샤 시아노페닐 유도체
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
EP1495005A1 (en) 2002-04-12 2005-01-12 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
JP2007521282A (ja) 2003-07-02 2007-08-02 メルク アンド カンパニー インコーポレーテッド オキサゾリジノン抗生物質およびその誘導体
KR20060097024A (ko) 2003-09-30 2006-09-13 얀센 파마슈티카 엔.브이. 벤조이미다졸 화합물
NZ547696A (en) 2003-12-23 2009-12-24 Astex Therapeutics Ltd Pyrazole derivatives as protein kinase modulators
EP1775289B1 (en) 2004-08-03 2011-03-30 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivatives
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
WO2006058649A1 (en) 2004-12-03 2006-06-08 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as h3 antagonists
KR20230003445A (ko) * 2005-05-13 2023-01-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
SG170809A1 (en) 2006-03-29 2011-05-30 Univ California Diarylthiohydantoin compounds
TW201716385A (zh) 2007-10-26 2017-05-16 加州大學董事會 二芳基乙內醯脲類化合物
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
AU2010294588A1 (en) 2012-04-05
ECSP12011716A (es) 2012-04-30
PE20121180A1 (es) 2012-08-24
KR20120065396A (ko) 2012-06-20
IL218390A0 (en) 2012-04-30
UY32882A (es) 2011-04-29
EP2475653A1 (en) 2012-07-18
CN102639523A (zh) 2012-08-15
MA33566B1 (fr) 2012-09-01
CO6511228A2 (es) 2012-08-31
CA2773591A1 (en) 2011-03-17
WO2011029537A1 (en) 2011-03-17
CL2012000623A1 (es) 2012-09-14
MX2012002977A (es) 2012-04-30
SG178919A1 (en) 2012-04-27
CR20120113A (es) 2012-05-02
TW201111378A (en) 2011-04-01
TN2012000108A1 (en) 2013-09-19
BR112012005526A2 (pt) 2016-04-26
IN2012DN02081A (ru) 2015-08-21
US20120251551A1 (en) 2012-10-04
NZ598643A (en) 2013-10-25
CU20120042A7 (es) 2012-06-21
JP2013504523A (ja) 2013-02-07
DOP2012000063A (es) 2012-05-15
AR078166A1 (es) 2011-10-19

Similar Documents

Publication Publication Date Title
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
UA115983C2 (uk) Інгібітори днк-пк
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
EA201500362A1 (ru) Ингибиторы rho-киназы
EA201171367A1 (ru) Винилиндазолильные соединения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX356205B (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EA201001639A1 (ru) Композиции и способы их получения и применения
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
EA020330B3 (ru) Хиназолиновые соединения
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
UA112795C2 (uk) Біциклічні піразинонові похідні
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use
EA202091923A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr